Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Genelux Corp.

Headquarters: San Diego, CA, United States of America
Year Founded: 2001
Status: Public
Industry Sector: HealthTechnology
CEO: Thomas D. Zindrick
Number Of Employees: 23
Enterprise Value: $321,582,185
PE Ratio: -3.75
Exchange/Ticker 1: NASDAQ:GNLX
Exchange/Ticker 2: N/A
Latest Market Cap: $123,646,800

BioCentury | Aug 28, 2023
Management Tracks

Kurt Graves takes top spot at i2o

Plus: Lourie Zak becomes CFO at Genelux, and updates from Delve Bio, Leo, and Synthetica
BioCentury | Jul 21, 2023
Management Tracks

Janssen vet Vratsanos joins Jnana as CMO

Plus: CureVac’s Splawski lands at Yarrow and updates from Genelux, Cour and more
BioCentury | Nov 16, 2021
Data Byte

The oncolytic virus pipeline

At least 49 oncolytic virus therapies now in development behind the sole FDA-approved product
BioCentury | Jan 24, 2018
Company News

Management tracks: Gritstone, Disarm, Symic

BioCentury | Aug 15, 2016
Clinical News

GLV-1h68: Phase Ib started

BioCentury | Aug 15, 2016
Clinical News

GLV-1h68: Phase Ib started

BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

How oncolytic viruses are coming of age in cancer immunotherapy combinations
BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

BioCentury | Jun 1, 2015
Clinical News

GLV-1h68: Phase I data

BioCentury | Jun 1, 2015
Clinical News

GLV-1h68: Phase I data

Items per page:
1 - 10 of 21